

# George LAU



MBBS (HK), MRCP(UK), FHKCP, FHKAM (GI), MD(HK), FRCP (Edin, Lond), FAASLD (USA)

Chairman, Humanity and Health Medical Group  
Director and Consultant, Humanity and Health Research Centre  
9 Queen's Road Central, Central, HKSAR, CHINA

Steering committee, Asia-Pacific Association for the Study of Liver

Professor in Translational Hepatology  
Co-director,  
The Institute of Translational Hepatology,  
Director, Beijing 302-Hong Kong Humanity and Health hepatitis C treatment Center,  
302 Military Hospital of China,  
100, the west of the 4th Ring Road, Beijing, China

**Email**

Email: [gkklau@hnhgml.com](mailto:gkklau@hnhgml.com)

Dr George Lau was trained in Internal Medicine and then specialized in Gastroenterology and Hepatology and obtained his fellowship from the Hong Kong College of Physician in 1995. He received his post-doctoral training in Hepatology at Stanford University from 1992–1994 (supported by Hong Kong–Stanford scholarship) and University College of London from 1998–1999 (supported by Royal Society Award). In 2002, he was promoted to Senior Lecturer and Consultant at the Department of Medicine, Queen Mary Hospital, The University of Hong Kong. At the same year, he was awarded The Most Outstanding Youth in Hong Kong. In 2005, he became the Global Principal Investigator of pegylated interferon  $\alpha$ -2a for the treatment of chronic hepatitis B (CHB) and his work led to the registration of pegylated interferon  $\alpha$ -2a by the EU and US Food and Drug Administration in 2005 (published in the New England Journal of Medicine with Dr. Lau as lead author). Dr. Lau has more than 500 publications with citation of over 10,000. He has also been invited to give numerous lectures in Hepatology throughout the world. Dr Lau had been the Associate Editor for both Journal of Hepatology and Liver international, and is currently serving as reviewer for over 30 international journals. In 2006, he was promoted to full Professor and assistant Dean, Faculty of Medicine, The University of Hong Kong. He was admitted to Fellow of the Royal College of Physician (London) in 2006. He was also well respected by his peer in academic Hepatology and was elected as 19<sup>th</sup> President of the Asian Pacific Association of the Study Liver (APASL) in 2008–2009. With his contribution in the field, he is now life-member of the Steering committee of APASL. In 2015, he was made fellow of the American Association for the study of Liver Diseases. In 2016, he was awarded National Science and Technology Progress Award (State Science and Technology Prizes)– Technological Advancement in Chronic hepatitis B infection management (China). In his community work, Dr Lau has founded the Cheng Si-Yuan (China-International) Hepatitis Research Foundation in 1998 (<http://www.csyfoundation.org>). This foundation represents one of the largest non-profit organisation in liver diseases in Asia. In 2009, he founded and become Chairman of Humanity and Health Medical Group, Hong Kong. He is also the co-Director, Institute of Translational Hepatology and Director of the Beijing 302-Hong Kong Humanity and Health hepatitis C treatment center, 302 Hospital, Beijing, China.